Loading data for RYTM — first visit, this takes a few seconds.
Rhythm Pharmaceuticals In... (RYTM)
NasdaqGM: RYTM
· Real-Time Price · USD
112.84
-2.64 (-2.29%)
At close: Aug 11, 2026, 8:00 PM
112.99
+0.13%
Pre-market: 7:30 AM
Rhythm Pharmaceuticals Inc. (RYTM) Stock Price, Analysis & Data
-2.29% (1D)
No data available
| Bid | 77.4 |
| Market Cap | 7.77B |
| Revenue (ttm) | 239.92M |
| Net Income (ttm) | -210.22M |
| Beta | 1.97 |
| EPS (ttm) | -3.12 |
| PE Ratio (ttm) | n/a |
| Forward PE | -184.56 |
| P/B (ttm) | 75.43 |
| P/S (ttm) | 32.26 |
| Earnings Date | Nov 3, 2026 |
| Ask | 140.85 |
| Volume | 728,454 |
| Avg. Volume (20D) | 791,675 |
| Open | 113.17 |
| Previous Close | 115.48 |
| Day's Range | 112.51 - 117.48 |
| 52-Week Range | 74.50 - 122.20 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syn...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2017
Employees 414
Stock Exchange NasdaqGM
Ticker Symbol RYTM
Website https://rhythmtx.com
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was 189.76M, an increase of 45.83% compared to the previous year's 130.13M. Earnings were -196.54M, a decrease of -24.58%.
Financial StatementsEarnings Surprise
Rhythm Pharmaceuticals has released their quarterly earnings on Aug 4, 2026:
Rhythm Pharmaceuticals Inc. is scheduled to release its earnings on Nov 3, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2